TCM Biotech International Corp. (TPEX:4169)

Market Cap	5.02B
Revenue (ttm)	666.53M
Net Income (ttm)	21.01M
Shares Out	59.05M
EPS (ttm)	0.36
PE Ratio	238.89
Forward PE	42.50
Dividend	0.35 (0.42%)
Ex-Dividend Date	Aug 28, 2025

Volume	51,982
Average Volume	315,012
Open	84.30
Previous Close	84.20
Day's Range	82.10 - 86.40
52-Week Range	43.65 - 95.60
Beta	-0.24
RSI	65.60
Earnings Date	Aug 10, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.